The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Sourcing · Regulatory

Labelling requirements for research chemicals — the long version

LS
l.salinasTL2 Moderator10 May 2026#1

Posting this under the heading it deserves: Labelling requirements for research chemicals — the long version Everything below is what sits behind that.

I would like to talk about documentation quality as a signal, separately from product quality.

Across the certificates I have collected, the variation in what is disclosed is much larger than the variation in the purity figures. Some name the analytical procedure; some give a number and a signature.

My hypothesis is that disclosure correlates with process control, and I would like to know whether the people who audit paperwork for a living think that is naive.

29 likes 3mo
DB
d.barrosTL2 Moderator25 May 2026#2

Off-label use and medical practice: clinicians can prescribe approved medications off-label under some circumstances. That is different from research-use-only compounds, which are not approved for any human use.

31 likes 2mo
HK
h.karlsenTL2 Moderator6 Jun 2026#3

Primary documents matter: regulatory positions are published in official documents. Reading the regulatory agency's website directly is more reliable than reading a forum summary of it.

1 like 2mo

Suggested topics

TopicParticipantsRepliesViewsActivity
What a regulator's shortage notice actually authorises — what changed since
The question in the title: What a regulator's shortage notice actually authorises — what changed since I will give what I have already checked below so nobody repeats it. A logistics question, since the…
JMMBUCRVW+22 26 53k 7mo
Research-use-only labelling: what it means and what it does not
Posting this under the heading it deserves: Research-use-only labelling: what it means and what it does not Everything below is what sits behind that. I would like to talk about documentation quality as a…
ZNPPJENGGR+100 110 37k 5mo
Coming back to: Research-use-only labelling: what it means and what it does not
Research-use-only labelling: what it means and what it does not — setting out what I have, and where I think it stops being reliable. Structured report rather than an opinion, following the format the…
RDCCAAPSDO+45 50 39k 20mo
Revisiting: Why a compound being unapproved is not the same as being illegal to possess
On the subject in the title: Revisiting: Why a compound being unapproved is not the same as being illegal to possess Working notes rather than a conclusion. Structured report rather than an opinion, following…
CHDVRARZMD+76 82 52k 11mo
Pharmaceutical compounding rules, summarised from primary sources
Pharmaceutical compounding rules, summarised from primary sources — setting out what I have, and where I think it stops being reliable. Structured report rather than an opinion, following the format the…
BJMBEDRIIL+135 163 46k 17mo

Related topics — sharing the tags MHRA, research use only, compounding

TopicParticipantsRepliesViewsActivity
Managing an unplanned gap in supply
Managing an unplanned gap in supply — setting out what I have, and where I think it stops being reliable. A coverage question with the paperwork detail included, since that is what determines the answer.…
LSFPASLCVK+105 110 5.1k 3mo
Payment mechanics and the recovery options that do not exist — what changed since
On the subject in the title: Payment mechanics and the recovery options that do not exist — what changed since Working notes rather than a conclusion. A logistics question, since the answers here are usually…
YRVBENBDCP+14 18 17k 13mo
Cost per delivered dose, which is the number that matters
Cost per delivered dose, which is the number that matters — setting out what I have, and where I think it stops being reliable. A coverage question with the paperwork detail included, since that is what…
MYFTATRFAD+54 59 30k 4mo
Second pass at: Reimbursement variation across member states
On the subject in the title: Second pass at: Reimbursement variation across member states Working notes rather than a conclusion. A coverage question with the paperwork detail included, since that is what…
APCDACBRSB+23 28 45k 21mo
[2026 update] Travelling with an injectable: documentation and practicalities
Travelling with an injectable: documentation and practicalities Writing it up because I had to work it out twice and would rather nobody else did. Documenting an access outcome, dated, because everything in…
VSDAWIBB+107 111 12k 1d